Table 3

Correlative studies

StudyDiseaseStudy Objectives
E4599Stage IV non-squamous, non-small cell lungTo determine whether pretreatment levels of plasma VEGFa predict response to chemotherapy with carboplatin/paclitaxel with or without bevacizumab
To determine whether pretreatment plasma VEGF is of prognostic value
To determine whether elevated plasma levels of endothelial cell-specific proteins (VCAM, E-selectin), reflective of chemotherapy or anti-VEGF-induced endothelial damage, are useful markers in assessing response to carboplatin/paclitaxel +/− bevacizumab
To determine whether pre- and post-treatment plasma levels of bFGF is of prognostic value or predictive of response to therapy
E2100Stage IV breast cancerTo compare changes in surrogate markers of angiogenesis and response, including VEGF and VCAM-1 expression, during treatment
E3598Stage IIIA–B non-small cell lung cancerTo determine the predictive power of sputum and serum to detect NSCLC through analysis for aberrant methylation of p16, MGMT, TIMP-3, and DAP-kinase within biological fluids
To determine whether the inactivation of p16, DAP-kinase, MGMT, or TIMP-3 genes in NSCLC can be used to predict survival
To determine whether the detection of a methylation biomarker in serum can be used to predict survival in patients with Stage-III NSCLC undergoing treatment with chemo/radiotherapy
E2898Stage IV renal cell carcinomaTo assess the pharmacodynamic effects of IFN and IFN plus thalidomide on pharmacodynamic measurements of angiogenesis such as plasma angiogenic factor levels (VEGF, TNF-α)
E1A00Stage III myelomaTo study the effect of thalidomide on bone marrow microvessel density and angiogenesis grade, and on the expression of VEGF and bFGF in the marrow
E2196Stage IV breast cancer, after first line therapyTo determine whether there is an association between trough plasma marimastat concentration and time to disease progression and toxicity, and between marimastat concentration and plasma MMP-9 level
  • a VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; NSCLC, non-small cell lung cancer; TNF, tumor necrosis factor; MMP, matrix metalloproteinase.